B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children
dc.contributor.author | Aggarwal, Sanjeev | en_US |
dc.contributor.author | Pettersen, Michael D. | en_US |
dc.contributor.author | Bhambhani, Kanta | en_US |
dc.contributor.author | Gurczynski, Joellyn | en_US |
dc.contributor.author | Thomas, Ronald | en_US |
dc.contributor.author | L'Ecuyer, Thomas J. | en_US |
dc.date.accessioned | 2007-12-04T18:36:11Z | |
dc.date.available | 2008-11-05T15:05:43Z | en_US |
dc.date.issued | 2007-11 | en_US |
dc.identifier.citation | Aggarwal, Sanjeev; Pettersen, Michael D.; Bhambhani, Kanta; Gurczynski, Joellyn; Thomas, Ronald; L'Ecuyer, Thomas (2007). "B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children." Pediatric Blood & Cancer 49(6): 812-816. <http://hdl.handle.net/2027.42/57395> | en_US |
dc.identifier.issn | 1545-5009 | en_US |
dc.identifier.issn | 1545-5017 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/57395 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17171687&dopt=citation | |
dc.description.abstract | Background Anthracyclines (AC) are useful antineoplastic agents, whose utility is limited by progressive cardiotoxicity. Our purpose was to evaluate plasma B-type natriuretic peptide (BNP), as a screening test for detecting late cardiac dysfunction in AC-treated children and to determine the prevalence of late cardiac dysfunction at low cumulative AC doses. Materials and Methods This was a prospective study in which patients who had completed AC therapy at least 1 year earlier, underwent a detailed echocardiogram and a simultaneous BNP level. Cardiac dysfunction was defined as any one of the following: shortening fraction (FS) <29%, rate corrected velocity of circumferential fiber shortening (VCFc) <0.9 c·sec −1 , end systolic wall stress (ESWS) >60 g·cm −2 , abnormal VCFc: ESWS ratio or decreased mitral inflow velocity (E/A) ratios, compared to age-specific norms. Results The cohort (n = 63) included 37 males with a median age of 13.1 years (range, 6.5–26.5 years). Cardiac dysfunction was found in 26 (41%) patients and in 40% of patients who received cumulative doses <150 mg·m −2 . ESWS was the most common abnormality. Mean BNP levels in the subset with abnormal function were significantly higher than the normal group (23.4 ± 25.3 vs. 14.2 ± 8.9 pg·ml −1 , P = 0.02). Conclusions Plasma BNP was significantly elevated in AC-treated patients with late cardiac dysfunction, although there was considerable overlap of levels between groups with and without cardiac dysfunction. BNP may need further evaluation as a serial index of cardiac function in this population. Cardiac dysfunction was observed in a significant proportion of patients, even at low cumulative AC doses. Pediatr Blood Cancer 2007;49:812–816. © 2006 Wiley-Liss, Inc. | en_US |
dc.format.extent | 124746 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, Michigan ; Division of Cardiology, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI 48201. | en_US |
dc.identifier.pmid | 17171687 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/57395/1/21100_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/pbc.21100 | en_US |
dc.identifier.source | Pediatric Blood & Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.